drugset

drugset / Trial / NCT07309055

A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

NCT07309055 ↗

Phase 3 Recruiting 201 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.

Timeline

Start: 2026-03-21
Primary completion: 2027-11
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-1819	Monoclonal antibody	—	—

Indications